RESUMO
Ketamine hydrochloride, pancuronium bromide and 100% oxygen were used during general anaesthesia for a left antero-lateral thoracotomy, insertion of a permanent cardiac pace-maker and ligation of a persistent ductus arteriosus in a three-month-old female infant, who was also in congestive cardiac failure. To the best of our knowledge, this is the first reported case of successful anaesthetic management for insertion of cardiac pace-maker and ligation of persistent ductus arteriosus under general anaesthesia in a Nigerian infant. The successful out-come of our anaesthetic technique encourages us to recommend the procedure for the anaesthetic management of similar complex cardiac abnormalities.
Assuntos
Anestesia por Inalação/métodos , Permeabilidade do Canal Arterial/cirurgia , Bloqueio Cardíaco/terapia , Insuficiência Cardíaca/complicações , Marca-Passo Artificial , Permeabilidade do Canal Arterial/complicações , Feminino , Bloqueio Cardíaco/complicações , Bloqueio Cardíaco/congênito , Humanos , Lactente , Ketamina/administração & dosagem , Ketamina/uso terapêutico , Oxigenoterapia , Pancurônio/administração & dosagem , Pancurônio/uso terapêuticoRESUMO
Changes in cerebral blood flow (CBF) in response to changes in PaCO2 were measured by intraaortic injection of 133Xe in 12 patients during hypothermic (23-30 degrees C) cardiopulmonary bypass. In each patient, CBF was determined at two randomly ordered levels of PaCO2 obtained by varying the rate of gas inflow into the pump oxygenator (Group I, n = 6) or by varying the percentage of CO2 added to the gas inflow (Group II, n = 6). Nasopharyngeal temperature, mean arterial pressure, pump-oxygenator flow, and hematocrit were maintained within a narrow range. In group I, a PaCO2 (uncorrected for body temperature) of 36 +/- 4 mmHg (mean +/- SD) was associated with a CBF of 13 +/- 5 ml X 100 g-1 X min-1, while a PaCO2 of 42 +/- 4 mmHg was associated with a CBF of 19 +/- 10 ml X 100 g-1 X min-1. In group II, a PaCO2 of 47 +/- 3 mmHg was associated with a CBF of 20 +/- 8 ml X 100 g-1 X min-1, and a PaCO2 of 53 +/- 3 mmHg was associated with a CBF of 26 +/- 9 ml X 100 g-1 X min-1. Within group I, the difference in CBF was significant (P less than 0.05); within group II, the difference in CBF was significant at the P less than 0.002 level. All CBF measurements were lower than those reported for normothermic, unanesthetized subjects of similar age.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Dióxido de Carbono/sangue , Ponte Cardiopulmonar , Circulação Cerebrovascular , Hipotermia Induzida , Idoso , Anestesia , Pressão Sanguínea , Feminino , Fentanila , Hematócrito , Humanos , Masculino , Pessoa de Meia-Idade , Oxigenoterapia , Pancurônio , Pressão Parcial , Medicação Pré-Anestésica , Radioisótopos de XenônioRESUMO
We have studied patterns of oxygen saturation (SpO2) before and after thoracotomy in 20 patients monitored nightly from the preoperative night to the fourth postoperative night. After operation, 10 patients received paravertebral bupivacaine (PVB) infusion and 10 received paravertebral saline (PVS) infusion. Papaveretum was given as required. Before operation the SpO2 profiles formed two groups: stable with SpO2 greater than 94% and stable with a median SpO2 less than 94% (hypoxaemia). During the first night after operation SpO2 profiles formed four groups: stable, not hypoxaemic (2/20); stable, hypoxaemic but improving (8/20); stable and constant hypoxaemia (5/20); unstable, hypoxaemic and deteriorating (5/20). Eleven patients remained hypoxaemic as late as the fourth night after operation. All patients who were hypoxaemic before operation were hypoxaemic after operation. Postoperative hypoxaemia was predicted in only 50% of cases. Papaveretum requirement was reduced in the PVB group, but regional analgesia did not affect the proportion of patients showing each SpO2 profile. Papaveretum caused a decrease in SpO2 in both analgesic groups.
Assuntos
Oxigênio/sangue , Complicações Pós-Operatórias/etiologia , Toracotomia , Adulto , Idoso , Bupivacaína/administração & dosagem , Feminino , Humanos , Hipóxia/etiologia , Masculino , Pessoa de Meia-Idade , Ópio/administração & dosagem , Ópio/efeitos adversos , Oxigenoterapia , Dor Pós-Operatória/terapia , Fatores de TempoRESUMO
UNLABELLED: In this study, we examined the effect of choice of neuromuscular blocking drug (NMBD) (pancuronium versus rocuronium) on postoperative recovery times and associated adverse outcomes in patients undergoing orthopedic surgical procedures. Seventy patients were randomly allocated to a pancuronium or rocuronium group. On arrival to the postanesthesia care unit (PACU) and again 30 min later, train-of-four ratios were quantified by using acceleromyography. Immediately after acceleromyographic measurements, patients were assessed for signs and symptoms of residual paresis. During the PACU admission, episodes of hypoxemia, nausea, and vomiting were recorded. The time required for patients to meet discharge criteria and the time of actual PACU discharge were noted. Forty percent of patients in the pancuronium group had train-of-four ratios <0.7 on arrival to the PACU, compared with only 5.9% of subjects in the rocuronium group (P < 0.001). Patients in the pancuronium group were more likely to experience symptoms of muscle weakness (blurry vision and generalized weakness; P < 0.001) and hypoxemia (10 patients in the rocuronium group versus 21 patients in the pancuronium group; P = 0.015) during the PACU admission. Significant delays in meeting PACU discharge criteria (50 min [45-60 min] versus 30 min [25-40 min]) and achieving actual discharge (70 min [60-90 min] versus 57.5 min [45-61 min]) were observed when the pancuronium group was compared with the rocuronium group (P < 0.001). In conclusion, our study indicates that PACU recovery times may be prolonged when long-acting NMBDs are used in surgical patients. IMPLICATIONS: Clinical recovery may be delayed in surgical patients administered long-acting neuromuscular blocking drugs. During the postanesthesia care unit admission, patients randomized to receive pancuronium (versus rocuronium) were more likely to exhibit symptoms of muscle weakness, develop hypoxemia, and require more time to meet discharge criteria.